Price T Rowe Associates Inc. MD Has $211,000 Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Price T Rowe Associates Inc. MD reduced its holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) by 95.7% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 19,918 shares of the company's stock after selling 442,601 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in ARS Pharmaceuticals were worth $211,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of SPRY. Alliancebernstein L.P. raised its stake in ARS Pharmaceuticals by 5,168.4% during the fourth quarter. Alliancebernstein L.P. now owns 3,880,734 shares of the company's stock worth $40,942,000 after acquiring an additional 3,807,074 shares during the period. Raymond James Financial Inc. bought a new position in shares of ARS Pharmaceuticals during the fourth quarter valued at approximately $6,576,000. Peregrine Capital Management LLC acquired a new stake in shares of ARS Pharmaceuticals during the 4th quarter worth approximately $4,469,000. Royce & Associates LP raised its position in shares of ARS Pharmaceuticals by 34.4% during the 4th quarter. Royce & Associates LP now owns 929,613 shares of the company's stock worth $9,807,000 after purchasing an additional 238,158 shares during the period. Finally, Levin Capital Strategies L.P. lifted its holdings in shares of ARS Pharmaceuticals by 56.2% in the 4th quarter. Levin Capital Strategies L.P. now owns 467,627 shares of the company's stock worth $4,933,000 after purchasing an additional 168,201 shares during the last quarter. 68.16% of the stock is owned by institutional investors and hedge funds.

ARS Pharmaceuticals Trading Up 0.5%

SPRY stock traded up $0.07 during mid-day trading on Tuesday, reaching $14.33. 1,544,411 shares of the stock traded hands, compared to its average volume of 1,234,677. ARS Pharmaceuticals, Inc. has a 52-week low of $7.55 and a 52-week high of $18.51. The stock's fifty day moving average is $13.38 and its 200-day moving average is $12.86. The company has a market cap of $1.41 billion, a P/E ratio of -28.10 and a beta of 0.84.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.35) EPS for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analysts' expectations of $7.48 million. Equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current year.

Analyst Upgrades and Downgrades

SPRY has been the topic of a number of analyst reports. Scotiabank began coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a "sector outperform" rating and a $30.00 price objective on the stock. Oppenheimer started coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an "outperform" rating and a $40.00 target price for the company. Finally, William Blair reaffirmed an "outperform" rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Eric Karas sold 10,000 shares of the business's stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the transaction, the insider now owns 7,696 shares in the company, valued at $107,744. The trade was a 56.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Laura Shawver sold 49,600 shares of ARS Pharmaceuticals stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the sale, the director now owns 210,346 shares of the company's stock, valued at approximately $2,357,978.66. This represents a 19.08% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,602 shares of company stock valued at $1,311,041 in the last three months. 33.50% of the stock is currently owned by company insiders.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.